Skip to main content


Health

Novartis says that it now seeks approval for serelaxin. Researchers say that in a study of 1,161 patients, the drug cut deaths from any cause at six months by 37 percent and led to a marked reduction in worsening of heart failure during hospitalization.
676 of 1663




Newsletter Sign Up

Saint of the Day

March 5 Saint of the Day

St. John Joseph of the Cross
March 5: St. John Joseph of the Cross was born about the middle of ... Read More